Sign inCreate account

Report workspace tools

NCT04620187RECRUITINGanonymous

A Phase II Study of Adjuvant Ado-trastuzumab Emtansine (T-DM1) in HER2-positive Salivary Gland Carcinomas

Sponsor

Source record

Dana-Farber Cancer Institute

Phase

Source record

Phase II

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

HER2-positive Salivary Gland Carcinomas

Indication / condition

AI-normalized

Salivary Gland Cancer

Intervention

Source record

Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy, Standard of Care Chemotherapy

Source & freshness

Source record

NCT ID

NCT04620187

Original source

ClinicalTrials.gov

Source last updated

Apr 13, 2026

Ingested at

Jun 05, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04620187

Title

A Phase II Study of Adjuvant Ado-trastuzumab Emtansine (T-DM1) in HER2-positive Salivary Gland Carcinomas

Sponsor

Dana-Farber Cancer Institute

Status

RECRUITING

Phase

Phase II

Condition raw

Salivary Gland Cancer, HER2 Gene Mutation

Condition normalized

Salivary Gland Cancer, HER2 Gene Mutation

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy, Standard of Care Chemotherapy

Target normalized

HER2-positive Salivary Gland Carcinomas

Interventions

Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy, Standard of Care Chemotherapy

Public preview

Source record

This clinical trial, sponsored by Dana-Farber Cancer Institute in collaboration with Genentech, investigates the safety and efficacy of Ado-trastuzumab emtansine (T-DM1) combined with standard chemoradiation in patients with HER2-positive salivary gland cancer. The trial aims to establish a treatment protocol for a cancer type lacking FDA-approved therapies.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase II Study of Adjuvant Ado-trastuzumab Emtansine (T-DM1) in HER2-positive Salivary Gland Carcinomas

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04620187

Status

RECRUITING

Phase

Phase II

Sponsor

Dana-Farber Cancer Institute

Executive brief

Investment-Ready Snapshot

This clinical trial, sponsored by Dana-Farber Cancer Institute in collaboration with Genentech, investigates the safety and efficacy of Ado-trastuzumab emtansine (T-DM1) combined with standard chemoradiation in patients with HER2-positive salivary gland cancer. The trial aims to establish a treatment protocol for a cancer type lacking FDA-approved therapies.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedApr 13, 2026
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04620187

Indication

Salivary Gland Cancer

Modality

monoclonal antibody

Target

HER2-positive Salivary Gland Carcinomas

Intervention

Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy, Standard of Care Chemotherapy

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.